Skip to main content

Table 2 Treatment Agent Comparisons

From: Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia

 

All Agents

Apixaban (N = 15)

Rivaroxaban (N = 14)

Dabigatran (N = 3)

P value €

Age, years

30–84 (median 65)

31–80 (median 67)

30–84 (median 60)

57–77 (median 66)

0.64

Gender

16 male, 16 female

7 male, 8 female

8 male, 6 female

1 male, 2 female

0.71

AF indication, N (%)

16 (50%)

6 (43%)

9 (60%)

1 (33%)

0.59

VTE indication, N (%)

16 (50%)

9 (57%)

5 (40%)

2 (66%)

0.59

Nosebleeds improved, N

1

0

0

1 }

0.044

Nosebleeds unchanged, N

7

4

2

1 }

Worse but tolerable, N

13

7†

5

1 }

Worse, treatment discontinued, N

11 ‡

4

7

0 }

  1. Treatment Agent Comparisons: † In one case only achieved after halving of the treatment dose. € p values calculated by the Chi squared test, except for age which was calculated by Kruskal Wallis. ‡ For the eleven episodes where DOAC treatment needed to be discontinued, subsequent management is described in the text and summarised in Additional file 1: Table S1. There was no difference between the 3 agents in recipient HHT status, genotype, or country/healthcare provider (data not shown)